Vir Biotechnology, Inc. (VIR) is an American biotechnology company headquartered in San Francisco, California. It's a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.
Vir has a broad portfolio of development programs that target hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and tuberculosis (TB). Its primary strategy is centered on applying immune programming to develop effective therapies for challenging infectious diseases.
Founded by a group of esteemed scientific researchers, including Dr. Robert Taylor, a pioneer in the field of infectious diseases, Vir Biotechnology, Inc. was incorporated in 2016. Since then, the company has made significant progress in its quest to create a world free from the burden of infectious diseases.
The VIR stock is traded on the NASDAQ under the ticker "VIR". The company has prominently garnered attention due to its proactive response to the COVID-19 pandemic. It prioritized developing novel therapies and vaccines to help stem the global outbreak. This endeavour led to the development of VIR-7831 and VIR-7832, monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19. VIR-7831, in partnership with GlaxoSmithKline plc, has shown considerable promise in early trials.
On top of its COVID-19 efforts, Vir has ongoing partnerships with various companies and organizations like Visterra, Alnylam Pharmaceuticals, Brii Biosciences, and the Bill & Melinda Gates Foundation. These collaborations aim to advance Vir's mission of addressing the world's most severe infectious diseases.
Despite being a relatively new player in the biotech sector, VIR has gained a reputation for its robust scientific acumen and dedication to innovative solutions. The future for Vir Biotechnology Inc. looks promising as it continues to work on its diverse pipeline of treatments and vaccines, reinforcing its position as a leader in immunology and infectious diseases.